Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Genuit buys Monodraught for £55.6m

(Sharecast News) - Genuit said on Monday that it has bought Monodraught - a provider of commercial ventilation solutions in the UK - for £55.6m. Monodraught focuses on solutions involving natural and hybrid ventilation. Genuit said it has a specific focus on the education sector, where it provides a "market leading" proposition.

Monodraught also provides high levels of technical support and design, continuing through to commissioning of customers' installations.

Genuit said the deal, which is expected to be accretive to earnings per share in the first full year of ownership, is "highly complementary" to the group's existing ventilation brands, Nuaire and Domus.

It will have minimal product or market overlap, providing an opportunity for Genuit "to bring commercial scale and market access beyond Monodraught's core".

Between 2021 and 2024, Monodraught delivered a 13% organic revenue compound annual growth rate. It has a high level of order book coverage underpinning continued strong revenue growth with an expected 2025 calendar outturn around £19m, Genuit said.

Chief executive Joe Vorih said: "I am delighted to welcome the Monodraught team to Genuit. They bring an innovative and highly complementary portfolio of ventilation products, as well as a controls and data management capability that extends our offering and enables us to integrate heating and cooling solutions from across the group.

"The acquisition significantly strengthens our position in the attractive UK ventilation market, which is benefiting from environmental and regulatory tailwinds. This is evident both in the strong growth of Monodraught in recent years alongside the demand for our existing portfolio of ventilation and low carbon heating and cooling products. We expect this to continue and are excited about the opportunities ahead."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.